In early November, IPHARMA received two approvals from the Ministry of Health of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm® medicinal products. Protocol № HEP-VTL-01 "A double-blind, randomized, placebo...
On May 22, 2017 IPHARMA received the Ministry of Health permission to conduct clinical trial of Phase I of the drug XC221. Protocol #ARI-XC221-01 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics...
On November 14-15, the 6th International Forum "Clinical trials in Russia" of the Adam Smith Institute was held in Moscow. IPHARMA was one of the major sponsors of the conference. This year, a large pool of interesting speakers including representatives...
On October, 26-28th, IPHARMA took part in the "Open innovations" Forum which was held in Skolkovo Technopark. IPHARMA’s stand was located in the showroom №14, where all the members of biopharmaceutical field could learn more about our company...
On November, 9th, IPHARMA took part in roundtable discussions at VIIth Russian Congress of Patients . The Congress has been conducted by Russian Patients Association since 2010. It is a unique platform for the dialogue between non-profit organizations for...
On April, 12 IPHARMA took a part in XXIV Russian National Congress “Human and drug” . The congress is the partner of Pharma 2020 Programm and aimed to scientific experience and knowledges exchange. Authentic information expansion is the main...
Since September 28th, IPHARMA will continue to hold a series of webinars in order to provide information to the vast media audience on variousaspects of clinical trials conduct. The company has an extensive experience in conducting trainings for the staff...
On June 2, ASCO Annual Meeting 2017, the main event of the year for specialists in the field of oncology, had started. Annually in Chicago, USA, more than 30,000 medical and pharmaceutical workers gather to discuss modern methods of treatment and innovative...
On November 13, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product AB5080. Protocol FLU-AV5080-02 “Multicenter, randomized, double-blind, placebo-controlled...
On May 30, 2017 IPHARMA received Ministry of Health permission to conduct a Phase I clinical trial of CD-008-0045. Protocol No. CD-008-0045 "A double-blind, randomized, placebo-controlled study of the safety, tolerability, and pharmacokinetics of increasing...
In August 2016, IPHARMA LLC was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase I clinical trial of medicinal product ИД 4025. Protocol № HCV-ИД4025-04 «Double-blind randomized placebo-controlled study to evaluate...
On September 18-19 , the annual educational course of the cluster of biomedical research of the Skolkovo Foundation for the Development of Innovative Drugs was held. Representatives of start-ups, pharmaceutical companies and contract research organizations...
In June 2017, the Eurasian Association for Quality Assurance started business. Experts of quality assurance system of clinical research have united to develop professional area, share experiences and create a community. ChemRar and IPHARMA have become...
IPHARMA has become an academic partner at the SkinHack event which will be held on November, 9-13th in Skolkovo Innovation Centre. The Hackathon applies methods of the machine vision, machine learning and artificial intelligence to analyze images and videos...
In 2016 IPHARMA signed scientific cooperation agreement with the I.M.Sechenov First Moscow State Medical University in which specialists of the company will participate in educational and research projects making educational materials and more. In October...
IPHARMA company celebrated 4th Birthday on September 8. Traditional picnic was on the territory of Technopark Skolkovo. We had a good time in a friendly and fun atmosphere by the lake. Our regular guest Big Jazz Orchestra performed the hits of The Beatles and...
On November 14-16, XXI Russian Oncology Congress passed in Moscow. It is one of the largest international events in the field of oncology, in which more than 5,000 doctors take part annually. Permanent organizers of the congress: N.N. Blokhin Russian...
On September 14 IPHARMA celebrated the 5th anniversary of the work in the market of clinical trials in the loft on the territory of "Crystal". More than 100 guests, including researchers, partners and customers congratulated IPHARMA. The holiday...
In October, 19th, at 11:00 AM, we will lead the webinar “Clinical trials in oncology introduction”. Register to the webinar What will we discuss at the webinar? Special aspects of clinical trials in oncology What you should pay attention...
In December 2017, IPHARMA received four approvals from the Ministry of health of the Russian Federation to conduct clinical trials. And, according to the results of 2017 (15 approvals), entered the TOP-3 CROs. - BE study of Aberon (abiraterone acetate) ...
We congratulate and are proud of Evgenia Ezhova, IPHARMA Project Manager, for the 3d team place in Russian Championship on Endurance horse rides for 80 km. International tournament Russian Championship was held in Spassk-Ryazansky, the Ryazan region, on...
Each year IPHARMA takes part in DIA (Drug Information Association) Global Conferences in Europe and the USA. During the event, participants share their views and knowledge and establish international contacts with potential partners and clients, which leads...
Разработчик программного обеспечения и провайдер услуг по обработке данных Data MATRIX и корейская компания Seoul CRO начнут совместную работу, направленную на внедрение IT-продуктов и облачных сервисов для клинических исследований на корейский рынок. Компании...
5 декабря компания Data MATRIX провела экспертную встречу «Новое поколение EDC для клинических исследований: новые возможности и новые бюджеты». В событии приняли участие эксперты, вовлеченные в процесс сбора и обработки данных в клинических исследованиях...
Institute for Atherosclerosis Research offers the service on organization and conducting of cross-sectional clinical trials in representative samples of 150-300 study participants in the field of novel biomarkers of atherosclerosis and atherosclerotic disease...